Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulse Dose Erlotinib and Gemcitabine in Second Line Advanced Pancreatic Cancer
NCT02154737Phase 1Completed
- Start
- Jul 2013
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erlotinib in pancreatic cancer (PC). Primary endpoint: Rate of dose limiting toxicities at 28 days. Started Jul 2013; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02154737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02154737.